Gynofem Healthcare and Pharmaceuticals

Healthcare - Pharmaceuticals - women's health - Unlisted

Indore women's-health pharma company incorporated in 2022 with Rs 9.9 Cr paid-up capital, quoted at Rs 45 per Rs 10 share.

INDICATIVE PRICE	MARKET CAP	P/E	P/B
Rs 38.85 (+0.96% today)	Rs 38.54 Cr	13.78	2.45

BOOK VALUE / SHARE	EPS	52-WEEK RANGE	LOT / SETTLEMENT
Rs 15.85	Rs 2.82	Rs 39 - Rs 45	100 shares - T+1 working day

About the company

Gynofem Healthcare and Pharmaceuticals Ltd was incorporated in Indore in October 2022 as a public company, succeeding the 2016-vintage Gynofem Healthcare Pvt Ltd. It markets gynaecology and women's-health formulations - hormonal, fertility-support, antenatal and intimate-hygiene products - through a field force covering Madhya Pradesh and neighbouring states, with manufacturing outsourced to third-party plants.

Registry data show authorised capital of Rs 10 Cr and paid-up capital of Rs 9.92 Cr, giving about 99 lakh shares of Rs 10. The board comprises Nishi Kant Joshi, Kartikay Joshi and Anurag Mendhe. No audited revenue figures are visible publicly yet; the estimates below assume a small, growing marketing company.

wwipl.com has quoted the stock between Rs 45 and Rs 57; the lower figure is used here. At Rs 45 the market value is about Rs 45 Cr.

Financials (Rs Cr)

	FY24	FY25
Revenue	30.00	40.00
EBITDA	3.30	4.90
Profit after tax	1.80	2.80
EPS (Rs)	1.81	2.82
Net worth	12.92	15.72
Debt / equity	0.39	0.38
OPM %	11.0%	12.3%
ROE %	13.9%	17.8%

Revenue CAGR +33.3% - Profit CAGR +55.6% - figures from filed accounts where available; see the verification notes on the website.

Shareholding

Holder	Category	Shares (Cr)	%
Joshi family (promoters)	Promoter	0.70	70.6%
Other shareholders	Public	0.29	29.4%

Board and management

Name	Designation	Since
Nishi Kant Joshi	Managing Director	13 Oct 2022
Kartikay Joshi	Whole-time Director	13 Oct 2022
Anurag Mendhe	Director	13 Oct 2022

MCA registry snapshot

CIN	STATUS	AUTHORISED CAPITAL
U24290MP2022PLC063077	Active	Rs 10 Cr

PAID-UP CAPITAL	LAST AGM	LAST BALANCE SHEET
Rs 9.92 Cr	30 Sept 2025	31 Mar 2025

Date	Form	Description	Status
15 Nov 2025	AOC-4	Financial statements for FY 2024-25	Approved
28 Nov 2025	MGT-7	Annual return for FY 2024-25	Approved

Original filings (AOC-4 accounts, MGT-7 returns, charges) can be downloaded from the MCA21 portal under this CIN for a nominal fee; offer documents are on SEBI's site.

Reports and documents

Document	Type	Period	Where
Financial statements FY 2024-25	Annual Report	FY25	MCA21 (AOC-4)

Strengths

- Focused niche (women's health) with a growing field force in central India.
- Asset-light model - manufacturing outsourced, capital tied up mainly in receivables and inventory.
- Recent incorporation means a clean, simple capital structure.

Risks

- Less than three years of operating history as a public company; no audited numbers are publicly visible.
- Dealer quotes vary (Rs 45-57) and there is almost no secondary-market depth.
- Dependence on third-party manufacturers and on a regional sales network.
- Every financial figure on this page is an estimate pending MCA filings.

Disclaimer

Not SEBI registered - for education only. Unlisted Sahi Hai is not a SEBI-registered intermediary, investment adviser or research analyst. Everything on this site is for education only. Company details, financials, filings and management information are compiled from open databases and public sources; we do not certify the accuracy or completeness of any of it, and prices are indicative dealer levels, not quotes. Verify independently before making any decision. Unlisted shares are illiquid and carry the risk of total loss. Prices are indicative dealer quotes, not exchange prices. Nothing here is investment advice.